- Open Access
Prostaglandin E2 binding peptide screened by phage displaying: a new therapeutic strategy in rheumatoid arthritis
Lipids in Health and Diseasevolume 10, Article number: 75 (2011)
To investigate the therapeutic potential and mechanism of action of the mimotope of PGE2 receptor EP4 (PBP, named by our team) screened by phage displaying technique in the treatment of adjuvant-induced arthritis (AA).
Freund's complete adjuvant-induced arthritis was induced in Wistar rats. At the first clinical sign of disease, mice were given with daily injections of PBP or saline for 21 days. Disease progression was monitored by measurement of paw swelling. Inflammation and joint destruction were assessed histologically. The IL-1β and TNF-α were studied by ELISA in the ankle steeps of arthritis model. The degree of proliferation and apoptosis of synoviocytes of RA patients were assessed by CCK-8 kit and Annexin⊠-FITC/PI respectively.
PBP-treated animals displayed significantly less cartilage and bone destruction than model controls. Tumor necrosis factor α and IL-1β expression were reduced after PBP treatment. The proliferation and apoptosis of synoviocytes of RA patients were influenced by PBP.
The data support the view that PBP is a potential therapy for RA that may help to diminish both joint inflammation and destruction. And the activities of PBP are related with the effect on synoviocytes directly.
RA is characterized by systemic and local inflammation resulting in cartilage and bone destruction. Non-steroidal anti-inflammatory drugs (NSAIDs), which represent an effective therapy for treating RA, elicit their effects by inhibiting cyclooxygenase (COX) activity and blocking the downstream production of prostaglandin, including prostaglandin E2 (PGE2). And the major medicine treating RA is COX-2 selective inhibitor. However, this kind of medicine has side-effects such as cardiovascular effects [1, 2], which have limited its use. PGE2 is the most important molecule in the pathogenesis of rheumatoid arthritis , which can be secreted by a lot of cells including macrophage cells and synovial fibroblast. Moreover, PGE2 is one of the main products of cyclooxygenase in a number of physiological settings. The diverse effects of PGE2 may be accounted for in part by the existence of four receptors, designated EP1, EP2, EP3, and EP4 [4, 5], and heterogeneity in the coupling of these receptors to intracellular signal transduction pathways. In RA, EP2 and EP4 receptors, especially EP4 receptor , are the major ones which couple to the Gs-type G protein leading to stimulation of cAMP.
Then specific mimotope of PGE2 receptor may prevent the binding between PGE2 and receptor, which may be an effective treatment method on RA. Phage displaying technology has abroad application in the study of reorganization of protein molecules, development of new vaccine and new drug. Its greatest advantage is providing some libraries where the target-specific binders can be selected conveniently. So we have used the phage displaying technique to select C-X7-C peptides with PGE2 as the target and named these peptides PBPs (PGE2 binding peptide) and regarded the PBPs as a mimotope of EP4 . Moreover, some reports have demonstrated that the key binding sites between PGE2 and receptor are related with arginine and threonine [8, 9]. So we have selected one peptide of which the sequence is CANRTSKNC to synthesize.
In the present study, we generated RA rat models and treated them with PBP. It was found that this treatment could reduce arthritis severity and footpad swelling. To investigate the therapeutic effect and the mechanism of this mimotope in RA, we detected its anti-inflammatory effect furthermore and demonstrated this mechanism in vivo and in vitro.
Materials and methods
Male Wistar rats weighing 160 g-180 g, were purchased from the animal center of our university. All animals were placed at a controlled temperature (22°C-28°C), and a regular light/dark cycle (6:00 to 19:00 h, light), and all animals had free access to food and water.
PGE2 was bought from Jingmei Lt and PGE2 ELISA kit was from the Suzhou Hematology Research Centre. ELISA kits for IL-1β and TNF-α were Ebioscience products. Celecoxib was purchased from Pfizer Pharmaceuticals Limited product. All enzymes were from TaKaRa Biotechnology (Dalian) co.ltd. Freund's complete adjuvant (FCA) was from Beijing Dingguo Biotechnology co. ltd. CCK-8 kit was purchased from Dojindo.
Theoretical structure model of PBP and PGE2 were obtained using the HOMOLOGY module of the Insight II 2000 software firstly. The surface and interior between PBP and PGE2 were distinguished and the best connection between them was determined with computer graphics technology. The most acceptable solution was determined and optimized using Discover Module of Insight II (2000) software package. The Discover_3 program was used to generate the low-energy conformation of the complex.
Induction and treatment of arthritis in rats
Rat AA was induced as previously described . Briefly, The rats were immunized by subcutaneous injection into the left-hind paw with 0.1 ml Freund's complete adjuvant (FCA), containing 10 mg heat-inactive BCG in 1 ml paraffin oil. All procedures were approved by University Committee on the use and care of laboratory animals. Arthritis usually developed 6 days later after immunization. The rats were considered to have arthritis when significant changes of redness and/or swelling were noted in the digits or other parts of the paw. The animals were assigned to one of five groups at random, in which they were treated intraperitoneally with 10 ug/kg, 20 ug/kg, and 40 ug/kg PBP per injection, with 12.5 mg/kg celecoxib 0.5 ml as positive control, with 0.5 ml saline as negative control. Treatment was started on the seventh day after this disease was induced. All groups were treated daily for 21 days. Thereafter, the rats were killed by cervical dislocation and the hind paws and sera were collected and used for further analysis. The in vivo experiments were performed with 6 rats per group.
Evaluation of arthritis activity
Rats were inspected daily for signs of arthritis by an independent observer who was not aware of the treatment. After 21 days of treatment, rats were killed and their paws were processed for histopathological evaluation.
ELISA for inflammatory cytokines IL-1β and TNF-α in ankle steeps
In order to detect the cytokine level in the ankles, whole ankle joints were cut after rats were anaesthetized and dipped in PBS for 24 h after the skin and parenchyma were cut open. The ankle steeps were collected and stored in a -20°C refrigeratory for the next tests. TNF-α and IL-1β in the samples were measured using enzyme-linked immunoassay kit (ebioscience company rats TNF- a and IL-1β ELISA kit), according to the manufacturer's protocol. Briefly, ankle steeps were added to wells from 96-well plate precoated with 100 ul/well capture antibody and incubated for 2 h at 37°C. After wash, detection antibody were added and incubated for 1 h at 37°C. After another wash, horseradish peroxidase (HRP) labeled anti rat IgG goat antibodies were added and also incubated for 2 h at 37°C, After the final wash, the presence of HRP-labeled Abs was revealed by addition of o-phenylenediamine (OPD) and the reaction was stopped with sulfuric acid (2N). The coloration was evaluated by optical density at 490-630 nm.
Whole ankle joints were fixed in 5% formalin at 4°C for 24 h. Subsequently, joints were decalcified in 10% ethylene diamine tetraacetate (EDTA) in buffered formalin (5.5%) for 4 weeks, and processed for histology by routine paraffin embedding, sectioning (4 μm), and staining using hematoxylin and eosin (H&E) and examined for the degree of synovitis and bone erosions by microscopic evaluation in a blinded manner as described earlier. Bone erosions were scored using a semiquantitative scoring system from 0 to 4 (0 = no erosions, 4 = extended erosions and destruction of bone).
Isolation of synoviocytes
Synovial tissues were obtained from RA patients who met the American Rheumatism Association criteria for classification and had undergone joint replacement surgery (5 women, 2 men; 55 ± 2 years). The study was approved by the local ethics committee, and informed consent was obtained from each patient enrolled. The synovial samples were digested and subsequently cultured as described by Zimmermann et al . Synovial fibroblasts were isolated by enzymatic digestion of synovial tissues obtained. Synovial tissues were minced into 3-5 mm pieces and treated for 4 h with 4 mg/ml of typellcollagenase (Sigma Chemical Co., St Louis, MO, USA) in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL., Grand Island, NY, USA) at 37°C in 5% CO2. Dissociated cells were then centrifuged at 2000 rpm and resuspended in DMEM supplemented with 20% fetal calf serum (FCS), 100 units/ml penicillin, and 100 mg/ml streptomycin, and plated in 6 well culture plates. The next day, cultured plat was vigorously rinsed to remove non-adherent cells with fresh DMEM, and adherent synovial fibroblasts were cultured in DMEM supplemented with 10% FCS. The cultures were kept at 37°C in 5% CO2, and the medium was replaced every 4 days. The cells were morphologically homogeneous and had the appearance of fibroblast, with typical bipolar shown. We named them as HSY (Human Synoviocyte Yan). All the experiments described below were conducted using cells at the 4-10 passage. The experiments were done as follows.
Synoviocytes proliferation assay
The synoviocytes were suspended in DMEM medium with 10% FCS at a concentration of 1 × 105 cell/ml. The cell suspension of 100 μl were added to 96-well flat-bottomed culture plate and incubated at 37°C, in 5% CO2 for 24 h. After the cells adhered, PBP with different concentrations were added to the well, 5 μM, 2.5 μM, 1.25 μM, 0.625 μM, 0.3125 μM, and DMEM with 10% FCS as a negative control and incubated at 37°C, in 5% CO2 for 48 h. Then incubation were added with 10 μl WST-8 from CCK-8 kit (Dodindo, Japan) to each well, oscillated for 1 min on oscillator and incubated at 37°C and in 5% CO2 for 1.5 h continuously. After incubation, the absorbance (A) was measured at 450 nm.
Apoptosis detection kit (Annexin V binding)
The assay was performed according to the instructions of the manufacturer. FLS were seeded at 1 × 105cells/well and incubated for 24 h, then were treated with 5 μM PBP and 40 μM celecoxib, and PBS (phosphate-buffered saline) as a negative control. After 24 h, Cells were trypsinized, counted and sedimented, then washed with cold PBS, and resuspended in 500 μl binding buffer. Fluorescein isothiocyanate conjugated Annexin V (10 μl) and PI (10 μl) were added to each samples, and the mixture was incubated at 4°C in the dark for 5 min. Then the cells were immediately subjected to FACS analysis (BD FAC-S Calibur, USA).
Hochest 33342 and PI staining
Cells growing in exponential phase were seeded at 2.5 × 104 cells in 2 ml of DMEM with 10% FCS in a 6 well culture plate with a cover slip and incubated in a 5%CO2 atmosphere. Cells were exposed to 5 μM PBP and 40 μM celecoxib, and PBS as a negative control. The morphology of treated and untreated cells was examined following incubation for 72 h. Cells were washed with PBS three times and then stained with 10 μl Hoechst33342 nuclear dye (working concentration was 5 μg/ml) in 2 ml of DMEM for 10 min at 37°C. After washing with PBS 3 times, cells were added with 2 ml new of DMEM and 30 μl PI (working concentration was 1.5 μg/ml) for 10 min at 4°C. After another washing with PBS for 3 times, images were obtained by confocal fluorescence microscope (Olympus-FV1000, Japan). The average of the apoptotic cells in each of the respective groups was determined as a percentage of the control (untreated cells).
Differences between treatment groups were tested by one-way ANOVA and unpaired two-tailed Student' test. The data were expressed as the mean ± SEM. Analysis of variance of repeated data measured with SPSS 13.0, and P values less than 0.05 at 95% confidence level were considered significant.
3-D modeling structures of PBP and PGE2
The 3-D complex structure suggested that there formed hydrophobic interaction between PBP and PGE2 (Figure 1A and 1B), and the interaction energy between PBP and PGE2 was -11.4036 KJ/MOL, in which the VDH is -5.38675 KJ/MOL. So certain conclusions and predictions could be drawn from the results that the interaction between PBP and PGE2 had a relatively stable structure.
PBP reduces the paws inflammation of AA
To examine whether PBP therapy could be effective in the treatment of AA, rats were given with a daily intraperitoneal injection of various dosages of PBP or saline for 21 days. All animals were treated on the seventh day after immunization. All groups treated with PBP showed a 70% decrease in paw swelling compared to controls (P < 0.05) (Figure 2). There was no clear dose dependency in peptide treatment groups, suggesting that all dosages were in the therapeutic range with regard to effects on clinical signs of arthritis. The effect of PBP treatment on synovial inflammation was also assessed in histology. Wild-type rats showed no inflammation and destruction at all by H&E (Figure 3A) from histopathology of the ankle joints, while model groups showed heavy cell infiltration, neovessel growth, synovial cell proliferation, and pannus formation in tissues of AA rats (Figure 3B). And peptide treatment groups showed a marked destruction and infiltration compared with model groups (Figure 3C). It was found the histologic score decreased after PBP treatment compared with model groups (P < 0.05) but did not reach the normal level (Figure 3E).
PBP pervasively suppresses TNF-α and IL-1β in inflammatory tissues of AA
In particular, cytokines secreted from synoviocytes, such as TNF-α and IL-1, were considered major determinants in the perpetuation of arthritis . TNF-α is a pro-inflammatory cytokine which may induce the proliferation of synoviocytes and enhance their production of cytokines such as TNF and IL-1 in situ, which largely show the pathology of arthritis. It also largely accounts for the pathology of autoimmune-related arthritis . We then studied whether the level of TNF-α and IL-1β was decreased in the synovium of AA by PBP. ELISA showed that the level of TNF-α and IL-1β in the ankle steep were reduced by intraperitoneal PBP (Figure 4). There was also no obvious dose dependency in peptide treatment groups (data not shown).
Effects and Mechanism of PBP Inhibitors on Synovial
Synovial hyperplasia was thought to play an important role in the development of AA which was caused by an increased rate of proliferation of FLS. Through CCK-8 assays, we had observed that PBP treatment groups could inhibit the synovial fibroblast proliferation compared with non-PBP groups. The inhibitory percent could arrive at about 50% (Figure 5). This was the evidence that PGE2 might be a mitogen which could promote synovial fibroblast proliferation. Therefore, this peptide through screening phage library with PGE2 as a target could inhibit PGE2 to interact with its receptor EP4 .
On the other hand, two methods were used to value the effects of PBP on FLS apoptosis. From the pictures of laser scanning confocal fluorescence microscope (Figure 6A-6C), we had observed viable cells, apoptotic, and necrotic cells. Moreover, the Hoechst33342 dye stained the nuclei of all cells; therefore apoptosis might show nuclear changes such as chromatin condensation and nuclear fragmentation. So in PBP treatment groups, we could see these changes (see what was directed by arrow in Figure 6B). While PI uptake indicated the loss of membrane integrity characteristic of necrotic and late apoptotic cells because PI was excluded from viable and early apoptotic cells (Figure 6C); in combination with fluorescence microscopy, selective uptake of the two dyes allowed one to monitor the induction of apoptosis in intact cultures and to distinguish it from non-apoptotic cell death (necrosis). Necrosis was characterized in this system by nuclear PI uptake without chromatin condensation or nuclear fragmentation, but this did not reach statistical significance. We also used AnnexinV-FITC and PI double staining with FACS to detect the effect of PBP on FLS apoptosis. We could see the percent of early apoptosis cells was 6.5 ± 2.2% in PBP treatment groups which increased by 1.7% than FLS negative control groups. While the percent of later apoptosis and necrosis was 14.05 ± 3.0, which exceeded FLS negative control groups by 4.05% (Figure 6D and 6E).
In 2002, McCoy and their groups showed that prostaglandin EP4 receptor, but not EP1, EP2, EP3 receptor-deficient mice decreased the incidence and severity of disease in the mouse arthritis model, suggesting that the mimotope of the prostaglandin EP4 receptor might provide novel agents for the treatment of rheumatoid arthritis . Moreover several researchers had found that mimotope of the prostaglandin EP4 receptor such as CJ-042,794 [6, 14] had the comparable effects on inhibiting inflammation process compared with non-selective COX inhibitor (piroxicam) and selective COX-2 inhibitor (rofecoxib). So how to select the mimotope of the prostaglandin EP4 receptor became the key point for searching effective medicines [15, 16].
Through phage-peptide library, high affinity and specific peptides can be isolated which could be made into a new type medicine of treating diseases [17, 18]. Phage displaying technology is a high-throughout screening (HTS) assay for studying the binding site of ligands and receptors, searching for the ligand molecules with high affinity and detecting the dimensional structure epitopes of unknown protein, which has an abroad application in the study of reorganization of protein molecules, development of new vaccine and new drug. Moreover, it plays an important role on the simulating epitopes, identifying the major animos between proteins interaction. The Ph.D-C7C is to link the genotype of short peptide displaying on the phage surface with the phenotype closely. Rapid enrichment of library clones encoding binding polypeptides is achieved by phage library incubation with a target followed by removal of the non-reacting phage and amplification of binder clones in the host bacteria [19–21]. Usually, three to five rounds of panning are sufficient to enrich for binding peptide sequences. In our studies, we have selected the mimotope of the prostaglandin EP4 receptor, which is named by PBPs. Moreover, we had employed the Molecular Docking technology with Insight II 2000 software in SGI working station to analyze the three-dimensional structure of PBP and PGE2 . The lower energy indicates the high affinity between these two molecules, which provides the theoretical foundation for the next research.
With respect to the potential as a drug target in treating RA, our findings indicate that selective inhibition of PGE2 EP4 receptor will decrease the inflammation in ankles. This should markedly shift the balance away from the bone resorption that mediates osteolysis. It is of interest to see if future studies designed to investigate the effects of Cox-2 inhibition on the various other factors that stimulate inflammation and bone resorption in fibroblasts, as well as clinical trials, support this paradigm.
Although several labs have been able to demonstrate that Cox inhibitors can effectively block PGE2 synthesis, it has been demonstrated that this treatment can inhibit pro-inflammatory cytokine synthesis (e.g. TNF-α and IL-1) by these cells [23, 24]. Thus, it remains unclear how NSAID effectively inhibit synoviocytes proliferation. Synoviocytes were the ultimate targeting cells of pathological change of arthritis . PGE2 is an autocrine factor in rheumatoid arthritis, so its effect on the proliferation and apoptosis of synoviocytes should not be neglected. Through analysis of our results, it can be found that the prevention of interaction between PGE2 and its receptor EP4 by PBP can affect the cells proliferation in some degree, which is extremely beneficial for the treatment of RA.
Whereas IL-1 and TNF might be more important in the processes leading to cartilage and bone destruction and in limiting mechanisms involved in cartilage repair [26–28]. Tumor necrosis factor (TNF) antagonists (adalimumab, etanercept, infliximab) and TNF inhibitors (certolizumab pegol, golimumab) have been approved under the development respectively [29, 30]. Interleukin 1 (IL-1) antagonist (anakinra) has been approved to treat RA . So these two cytokines are better value to assess the degree of the arthritis and also good targets for treating the disease. It can be also found that PBP contributed to the reduction of pro-inflammatory cytokines TNF-α and IL-1, which maybe another mechanism of its anti-arthritis effects.
In conclusion, our results provide new relevant data of the mimotope activi ties of PGE2 receptor. PBP as a mimotope of EP4 has anti-inflammatory activities, which has been proved in vivo and in vitro. So the peptide screened by phage displaying technique has relevant therapeutic potential to the treatment of arthritis diseases.
Zarraga IG, Schwarz ER: Coxibs and heart disease: what we have learned and what else we need to know. J Am Coll Cardiol. 2007, 49 (1): 1-14. 10.1016/j.jacc.2006.10.003
Rao PN, Knaus EE: Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharmaceut Sci. 2008, 11 (2): 81s-110s.
De Mattei M, Varani K, Masieri FF, Pellati A, Ongaro A, Fini M, Cadossi R, Vincenzi F, Borea A, Caruso A: Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts. Osteoarthritis and Cartilage. 2009, 17 (2): 252-262. 10.1016/j.joca.2008.06.002
McCoy JM, Wicks JR, Audoly LP: The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest. 2002, 110 (5): 651-658.
Hata AN, Breyer RM: Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol & Ther. 2004, 103 (2): 147-166.
Miyaura C, Inada M, Suzawa T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T: Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem. 2000, 275 (26): 19819-19823. 10.1074/jbc.M002079200
Dongmei Yan, Leyang Yu, Lingbing Zhang, Yanni Lun, Wei Ma, Bairong Du, Xun Zhu: Screening the Antagonist of PGE2 Receptor in Adjuvant Arthritis by Phage Display. J of China Bioengineer. 2007, 27 (3): 83-87.
Negishi M, Irie A, Sugimoto Y, Namba T, Ichikawa A: Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of alpha- carboxylic acid of agonist and arginine residue of seventh transmembrane domain. J Biol Chem. 1995, 270 (27): 16122-16127. 10.1074/jbc.270.27.16122
Stillman BA, Audoly L, Breyer RM: A conserved threonine in the second extracellular loop of the human EP2 and EP4 receptors is required for ligand binding. Euro J of Pharmacol. 1998, 357 (1): 73-82. 10.1016/S0014-2999(98)00522-6. 10.1016/S0014-2999(98)00522-6
Latha RM, Geetha T, Varalakshmi P: Effect of Vernonia cinerea less flower extract in adjuvant-induced arthritis. Gen Pharmacol. 1998, 31 (4): 601-606. 10.1016/S0306-3623(98)00049-4
Zimmermann T, Kunisch E, Pfeiffer R, Hirth A, Stahl HD, Sack U, Laube A, Liesaus E, Roth A, Palombo-Kinne E, Emmrich F, Kinne RW: Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture-primary culture cells markedly differ from fourth-passage cells. Arthritis Res. 2001, 3 (1): 72-76. 10.1186/ar142
Arend WP, Dayer JM: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 1995, 38 (2): 151-160. 10.1002/art.1780380202
Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991, 10 (13): 4025-4031.
Murase A, Okumura T, Sakakibara A, Tonai-Kachi H, Nakao K, Takada J: Effect of prostanoid EP4 receptor antagonist, CJ-042, 794, in rat models of pain and inflammation. Eur J of Pharmacol. 2008, 580 (1-2): 116-121. 10.1016/j.ejphar.2007.10.054. 10.1016/j.ejphar.2007.10.054
Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y, Masuda M, Kato T, Okumura Y, Takada J: CJ-023, 423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther. 2007, 322 (2): 686-694. 10.1124/jpet.107.122010
Piazuelo E, Jiménez P, Strunk M, Santander S, García A, Esteva F, Lanas A: Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. Prostaglandins & other Lipid Mediat. 2006, 81 (3-4): 150-161. 10.1016/j.prostaglandins.2006.09.002
Hansen M, Wind T, Blouse GE, Christensen A, Petersen HH, Kjelgaard S, Mathiasen L, Holtet TL, Andreasen PA: A urokinase type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition. J Biol Chem. 2005, 280 (46): 38424-38437. 10.1074/jbc.M505933200
Steingroewer J, Bley T, Bergemann C, Boschke E: Biomagnetic separation of Salmonella Typhimurium with high affine and specific ligand peptides isolated by phage display technique. J Magn Magn Mater. 2007, 311: 295-299. 10.1016/j.jmmm.2006.10.1192. 10.1016/j.jmmm.2006.10.1192
Diamond SL: Methods for mapping protease specificity. Curr Opin Chem Biol. 2007, 11 (1): 46-51. 10.1016/j.cbpa.2006.11.021
Chen J, Bai G, Yang Y, Geng P, Cao Y, Zhu Y: Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay. Peptides. 2007, 28 (4): 928-934. 10.1016/j.peptides.2006.12.012
Larralde OG, Martinez R, Camacho F, Amin N, Aguilar A, Talavera A, Stott DI, Perez EM: Identification of hepatitis A virus mimotopes by phage display, antigenicity and immunogenicity. J Virol Methods. 2007, 140 (1-2): 49-58. 10.1016/j.jviromet.2006.10.015
Xiao He, Feng JN, Yu ZY, Zhang Lei, Ming Yu, He XH, Song Li, Shen BF, Yan Li: A5, a new small-molecule inhibitor of CD4 D1 obtained from a computer-aided screening method, contributes to the inhibition of CD4+T-cell function. J Biomol Screen. 2007, 12 (6): 800-808. 10.1177/1087057107305505
Lee YR, Kweon SH, Kwon KB, Park JW, Yoon TR, Park BH: Inhibition of IL-1 beta -mediated inflammatory responses by the IkappaB alpha super-repressor in human fibroblast-like synoviocytes. Biochem Biophys Res Commun. 2009, 378 (1): 90-94. 10.1016/j.bbrc.2008.11.002
Zhang X, Morham SG, Langenback R, Young DA, Xing L, Boyce BF, Puzas EJ, Rosier RN, O'Keefe RJ, Schwarz EM: Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris induced osteolysis. J Bone Min Res. 2001, 16 (4): 660-670. 10.1359/jbmr.2001.16.4.660. 10.1359/jbmr.2001.16.4.660
Hui A, Kulkarni GV, Hunter WL, McCulloch CA, Cruz TF: Paclitaxel selectively induces mitotic arrest and apoptosis in proliferating bovine synoviocytes. Arthritis Rheum. 1997, 40 (6): 1073-1084. 10.1002/art.1780400612
Newton RC, Decicco CP: Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha. J Med Chem. 1999, 42 (13): 2295-2314. 10.1021/jm980541n
Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, Gravallese E, Mathis D, Benoist C: Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 2002, 196 (1): 77-85. 10.1084/jem.20020439
Niki Y, Yamada H, Kikuchi T, Toyama Y, Matsumoto H, Fujikawa K, Tada N: Membrane-associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1 alpha transgenic mice. J Immunol. 2004, 172 (1): 577-584.
Haque UJ, Bathon JM: The role of biologicals in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2005, 19 (1): 179-189. 10.1016/j.berh.2004.08.010
Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M: Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006, 1069: 420-427. 10.1196/annals.1351.040
Bingham CO: Emerging Therapeutics for Rheumatoid Arthritis. Bull NYU Hosp Jt Dis. 2008, 66 (3): 210-215.
The authors were thankful to Weihai Peng and Dawei Gu (Department of orthopedics, First Hospital Jilin University) for providing us with the samples of RA patients to assure the research works smoothly going.
The authors declare that they have no competing interests.
XZ and DMY designed the study, WWH performed the bioinformation sequence and structural analysis, and others performed the experiments. DMY drafted the manuscript. All authors read and approved the final version of the manuscript.